On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry® (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.
Direct Participants in the Deal-Making
Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world. CBR® currently stores over 600,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored. Continue reading 5 Types of Cord Blood Market Participants Impacted by AMAG Pharma’s Acquisition of CBR®
Market Variation within the Global Cord Blood Industry
While the global cord blood banking industry first emerged in the 1990’s with the formation of two private cord blood banks within the United States, cord blood banks now exist across the globe. Cord blood banks are prominent throughout North American, South America, Europe, Asia, and the Middle East. However, this expansion has resulted in significant variation within the industry.
Continue reading An Executive’s Guide to Understanding Market Variation within the Cord Blood Industry
Short Summary: RoosterBio, Inc. and Sistemic have entered into an agreement to synergistically develop microRNA (miRNA)-based cell characterization technologies that will create more precise and relevant characterization panels for human mesenchymal stem cell (hMSC) products and in process cell banks.
Continue reading [ALLIANCE] Sistemic and RoosterBio Developing Regenerative Technologies Involving miRNA and Mesenchymal Stem/Stromal Cells
To create profitable products and services, stem cell industry executives need to stay informed about rapidly-evolving industry trends. For this reason, this post explores the most important trends within the induced pluripotent stem cell (iPSC) industry, as well as areas of geographical dominance.
Continue reading “Blockbuster” Year for Induced Pluripotent Stem Cells Provides Expanding Opportunities, with Japan at the Forefront of Global Innovation
The past few years have seen major change within the global cord blood banking industry, with new trends emerging, shifts in public perception toward cord blood storage, improving techniques for the use of cord blood in cellular therapy, and more.
The post below discusses important trends in cord blood storage that have emerged and the degree to which these trends are impacting cord blood banking market participants.
Continue reading Introduction to the Cord Tissue Market and Cord Tissue-Derived Mesenchymal Stem Cells (CT-MSCs)
What Are Induced Pluripotent Stem Cell (iPSC) Core Facilities?
Induced pluripotent stem cell (iPSC) core facilities are facilities created to facilitate the derivation and distribution of induced pluripotent stem cell lines. These facilities promote iPSC research advances by providing disease-specific iPSC lines to researchers, thereby allowing more researchers to study mechanisms of disease and new therapeutic applications.
Induced pluripotent stem cell core facilities can also provide services related to iPSCs, including consultation and technical services, as well as training in iPSC technology. Common services that the core facilities provide are derivation, maintenance, and characterization of iPSCs. They may also provide control iPSC lines, validated iPSC culture reagents, and more.
Continue reading A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities
Companies Developing Induced Pluripotent Stem Cell (iPSC) Therapies
There are currently are number of companies that are facilitating the development of induced pluripotent stem cell (iPSC) therapies, including:
- Cellular Dynamics International (CDI), owned by FUJIFILM Holdings Corporation
- ViaCyte, Inc.
- Fate Therapeutics
- Ocata Therapeutics
- And Others
However, Cellular Dynamics International (recently acquired by FujiFilm Holdings Corporation in April 2015) is arguably one of the most important market participants, because of its complete dominance in the area of iPSC product and therapy development.
Continue reading [CASE STUDY] The Dominance of Cellular Dynamics International / FUJIFILM Holdings within the Induced Pluripotent Stem Cell Market
The neural stem cell industry is a rapidly evolving industry. Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements. Sometimes they are announcements of major industry alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant funding award.
For those of us interested in the neural stem cell industry, tracking these shifting industry dynamics is of paramount importance. For this reason, this post covers the most significant neural stem cell industry news events as of June 2015.
Continue reading Neural Stem Cell Industry News Round-Up | June 2015
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have been commercialized in a number of different ways. iPSCs have been used as tools for drug development and discovery, for toxicology applications, in stem cell biobanking, in personalized medicine, and as research products. While each of these commercial applications is important, this post specifically considers the use of iPSCs as research products – meaning, tools that scientists use in their labs for research purposes and applications.
Specifically, this post explores the breakdown of induced pluripotent stem cells (iPSCs) research products, by category. This analysis is intended to direct the decision-making of research supply companies by indicating where there is high market demand at this time. (To learn about future directions for iPSCs, click here.)
Are you an executive at a stem cell company that offers induced pluripotent stem cell (iPSC) research products? Or, are you an investor in a company of this type? If so, have you wondered how much market competition exists for your products or services? Have you been curious as to the rate at which this competition is increasing? By focusing on these key points of understanding, you’ll be able to assess the technical attributes that matter, including what opportunities exist for expanding your product line and your customer reach.
iPSC research products have existed since 2006, the year in which Shinya Yamanaka’s team at Kyoto University first produced iPSCs from mouse cells. The discovery was a vital advancement in stem cell research, as it allows researchers to obtain pluripotent stem cells without the difficult legal, technical and ethical controversies that have long surrounded deriving cells from embryos. Yamanaka and his team reprogrammed adult mouse fibroblasts into iPSCs by introducing four reprogramming factors: Oct4, Sox2, c-Myc and Klf4. Subsequent work by James Thomson and colleagues replicated Yamanaka’s success with human cells and revealed additional factors, Nanog and Lin28, which facilitate the reprogramming process.
Continue reading The Market for Induced Pluripotent Stem Cell (iPSC) Research Products – Rate of Entrants, by Year
Introduction to the Stem Cell Biobanking Market
“Stem cell biobanking” is the cryogenic storage of stem cells, or biological samples containing stem cells, for use at a later point in time. Therefore, the “stem cell biobanking market” is defined as the total annual revenue derived from the storage of:
- Stem cell lines and their derivatives
- All biological samples that were collected specifically because they contain stem cell populations (e.g. cord blood, adipose tissue, and more)
For company executives and investors that are competing within the stem cell biobanking marketplace, it is important to know the nine market segments that compose the stem cell biobanking market at large.
Continue reading Stem Cell Biobanking Market: 9 Market Segments to Know
Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.
Every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events as of June 2015. Continue reading Induced Pluripotent Stem Cell News Round-Up| June 2015